Fund Manager Summary on PYC Therapeutics Ltd (ASX:PYC)
In February 2026, Firetrail Investments commented that PYC Therapeutics Ltd (ASX:PYC) develops RNA therapies for single‑gene diseases, citing strong primate data, encouraging early human safety signals and pivotal human readouts expected in 2026–2027, while noting a sizable potential market but that the program remains early and risky. Overall, fund managers view PYC Therapeutics as a clinically promising but still early‑stage biotech where April 2025 phase I/II VP‑001 data and patient anecdotes materially de‑risked the asset, while mid‑late 2025 corporate turbulence — a brief CEO resignation and reinstatement and subsequent board refresh — introduced governance and execution scrutiny that managers now see as being addressed by board changes and a clearer partnering/licensing focus; Firetrail emphasizes the large addressable markets (citing polycystic kidney disease as an example) and a market cap context, Salter Brothers highlighted the meaningful clinical readouts and used the share pullback to add to positions, and both managers point to actionable considerations: monitor upcoming human efficacy readouts and safety data, track progress on partnering/licensing and commercial pathway planning, and assess management and board stability as primary drivers of upside and downside given the program’s early stage, operational execution risks and market volatility.
Commentary From The Managers
There are 11 insights from 2 fund managers regarding their investment in PYC Therapeutics Ltd (ASX:PYC) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Firetrail Investments
6 Feb 2026
$1.50
Summary
- Firetrail Investments believes PYC Therapeutics is a compelling early-stage biotech opportunity and continues to hold because it targets single-gene disorders with an RNA approach, has strong primate data and early human safety signals, and offers substantial upside if clinical efficacy is demonstrated.
- Company focus: Targets single-gene genetic diseases; key example is autosomal dominant polycystic kidney disease (affects ~1 in 1,000 and can lead to kidney failure).
- Therapeutic approach: RNA-based therapy leveraging modalities popularized during COVID, designed to correct or mitigate single-gene defects.
- Preclinical evidence: Positive results in primate (monkey) studies demonstrating promising biological activity.
- Clinical progress: Human safety testing underway with encouraging tolerability signals; efficacy readouts anticipated in 2026 and 2027.
- Commercial potential: Current market cap ~US$1 billion; just the PKD indication implies a multi‑billion-dollar addressable market (cited ~US$15 billion) if efficacy translates to patients.
- Risk profile: High-risk, early-stage investment with binary upcoming clinical readouts that will materially de‑risk or re‑rate the opportunity.
- Investment rationale: Combination of differentiated biology, supportive primate data, emerging human safety signals and clear, near-term clinical catalysts underpin continued conviction.
Salter Brothers
23 Oct 2025
$1.22
Summary
- PYC Therapeutics Ltd faced leadership instability in September with the CEO's resignation and quick reappointment.
- Salter Brothers views Dr Hockings’ return and the board refresh as a net positive.
- Alan Tribe, Chair and major investor, is leading the board refresh.
- Professor Ian Constable has joined as a non-executive director, enhancing board expertise.
- Dr Rosenblatt and Mr Haddock have stepped down, streamlining the board and clarifying strategic priorities.
- The renewed board is focused on accelerating value realization through partnering and licensing opportunities.
- Salter Brothers notes that the share price has recovered significantly from the initial sell-off.
- The manager has taken advantage of the market dislocation to increase their position at favorable risk vs reward levels.
Firetrail Investments
30 Sept 2025
$1.02
Summary
- Firetrail Investments notes a turbulent month for PYC Therapeutics, marked by the CEO's resignation on September 17th and reinstatement on September 22nd.
- PYC is currently undergoing a Board refresh, which is expected to enhance its ability to navigate commercial pathways.
- The focus remains on the development of key RNA-based therapies, crucial for PYC's future prospects.
- Firetrail Investments continues to hold because of the potential improvements from the Board changes and the ongoing commitment to therapeutic advancements.
Salter Brothers
30 Apr 2025
$1.18
Summary
- PYC Therapeutics Ltd (ASX:PYC) provided clinical data from their phase I/II trial on the VP-001 drug asset.
- The data demonstrated clear meaningful efficacy, marking a significant de-risking point for the asset.
- Patient feedback highlighted the impact, with one stating they could see the white lid of a coffee cup with the treated eye.
- Another patient noted they now see airplanes, which they never did before.
- A third patient reported needing to reduce their eyeglass prescription.
- Salter Brothers is encouraged with the data and recognizes the ongoing progress in de-risking the asset.
Salter Brothers
31 Dec 2024
$1.31
Summary
- PYC Therapeutics Ltd (PYC) is a clinical-stage biotechnology company.
- They are advancing a pipeline of first-in-class drug candidates targeting significant unmet medical needs.
- In December, PYC announced the nomination of its fourth clinical drug candidate for Phelan-McDermid Syndrome, backed by encouraging preclinical data.
- Management has shown strong execution against established timelines, despite the share price not correlating with progress.
- Factors affecting the share price include the new Trump administration and RFK Junior's emergence, leading to increased uncertainty.
- Management is systematically de-risking the business through ongoing data generation.
- Salter Brothers is particularly focused on the upcoming RP11 MAD study readout, which could validate the halting of disease progression and damage reversal.
Firetrail Investments
31 Dec 2024
$1.31
Summary
- PYC Therapeutics underperformed during the month despite positive clinical trial data for PYC003 in Polycystic Kidney Disease (PKD) and VP-001 in Retinitis Pigmentosa type 11 (RP11).
- 2025 is anticipated to be a significant year for the company.
- PYC aims to move VP-001 into a registrational trial.
- Plans to enhance safety and efficacy data for PYC-001 in Autosomal Dominant Optic Atrophy (ADOA).
- PYC-003 is set to progress into human trials.
- With the FDA and big pharma focusing on disease-modifying gene therapies, PYC is expected to attract strong support from both domestic and offshore investors.
Salter Brothers
30 Sept 2024
$1.69
Summary
- Salter Brothers recognizes that PYC Therapeutics Ltd (PYC) experienced a strong month with significant developments.
- The FDA granted Rare Pediatric Disease designation to PYC's PYC-001 drug program, a key milestone for the company.
- This designation could enable PYC to receive a Priority Review Voucher upon approval, increasing the value of its drug development pipeline.
- PYC is preparing to commence human trials for PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA), an eye disease lacking current treatment options.
- Salter Brothers believes PYC’s innovative approach to addressing rare genetic diseases positions it favorably for future growth.
- The Manager remains bullish on the potential for further positive announcements from PYC in the near term.
Salter Brothers
31 Aug 2024
$1.29
Summary
- PYC Therapeutics Ltd (PYC) operates in the rare disease sector with a strong management team.
- PYC announced in August that its PYC-001 drug program received Rare Pediatric Disease designation from the FDA.
- This designation makes PYC eligible for a Priority Review Voucher upon approval, enhancing the value of its drug development pipeline.
- The company is preparing to commence human trials for PYC-001, reinforcing its position in precision therapies for genetic diseases.
- Salter Brothers continues to hold because of PYC's promising progress and significant potential in the industry.
Salter Brothers
31 July 2024
$0.93
Summary
- PYC Therapeutics (PYC) recently completed the first dose in its Multiple Ascending Dose study for Retinitis Pigmentosa type 11 (RP11).
- Safety and efficacy data are expected by year-end, which could further inform PYC’s potential.
- Progress is being made in other drug programs, with aims to advance three candidates into human trials by the end of 2024.
- Despite the subdued market response, Salter Brothers remains optimistic about PYC’s long-term potential.
- The Manager believes that PYC’s pipeline progress is a significant milestone for the company.
- Salter Brothers views the current market undervaluation as a compelling opportunity for investors.
Salter Brothers
30 June 2024
$1.19
Summary
- PYC Therapeutics Ltd (PYC) is a recent addition to the portfolio.
- PYC is an RNA therapeutics drug development company.
- In June, PYC announced significant progress in its drug development pipeline.
- Positive results were reported for its fourth drug candidate targeting Phelan McDermid Syndrome.
- Promising outcomes were noted in clinical trials for Retinitis Pigmentosa type 11 (RP11).
- These developments highlight PYC’s potential to deliver substantial value.
- Salter Brothers believes PYC is a valuable addition to the portfolio.
Salter Brothers
30 Apr 2024
$0.96
Summary
- PYC Therapeutics Ltd (PYC) is a newly added position in the Salter Brothers portfolio following an in-depth analysis of the biotech sector.
- The fund manager initiated a position due to PYC's focus on developing precision medicines for severe diseases with limited treatment options.
- PYC has three drug candidates that are expected to achieve human safety and efficacy read-outs within the next 18 months.
- These candidates specifically target critical conditions such as Retinitis Pigmentosa, Polycystic Kidney Disease, and Autosomal Dominant Optic Atrophy.
- Recently, PYC successfully raised A$74.6 million through an entitlement issue, in which the portfolio participated.
- With over A$100 million in cash reserves, PYC is positioned for financial stability and is well-equipped to support ongoing and future projects.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in PYC Therapeutics Ltd (ASX:PYC)?
Fund managers including Salter Brothers and Firetrail Investments have invested in PYC Therapeutics Ltd (ASX:PYC).
Why do fund managers invest in PYC Therapeutics Ltd?
Fund managers invest in PYC Therapeutics Ltd due to its promising clinical data from the VP-001 drug trial, which shows meaningful efficacy. This progress reduces risk associated with the asset. Additionally, the recent board refresh is expected to enhance strategic decision-making and commercial pathways for its RNA-based therapies. Despite recent leadership turbulence, the company's solid growth prospects in the biotech sector and attractive risk-reward profile encourage investment.
What happened to PYC Therapeutics Ltd (ASX:PYC)?
Fund managers have invested in PYC Therapeutics Ltd due to a recent leadership transition, where the CEO was briefly replaced but quickly reinstated, signaling resilience. The ongoing board refresh aims to enhance strategic direction and partnership opportunities for its RNA-based therapies. With key appointments and recent share price recovery, fund managers see a favorable risk-reward scenario, reinforcing confidence in the company's potential for value realization.
What is the short interest in PYC Therapeutics Ltd (ASX:PYC)?
The short interest in PYC Therapeutics Ltd (ASX:PYC) is 0.35% which makes it the 316th most shorted stock on the ASX. Of the 583.3M shares that PYC Therapeutics Ltd has on issue, 2.1M have been sold short.
What does PYC Therapeutics Ltd (ASX:PYC) do?
PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.